Krugliak Cleveland Noa, Masching Alexandra, Rubin David T
Inflammatory Bowel Disease Center, The University of Chicago Medicine, Chicago, Illinois, IL.
ACG Case Rep J. 2020 Aug 25;7(8):e00449. doi: 10.14309/crj.0000000000000449. eCollection 2020 Aug.
Ustekinumab is a monoclonal antibody against the p40 subunit of interleukin (IL)-12 and IL-23 and is US Food and Drug Administration (FDA)-approved for plaque psoriasis, moderately to severely active Crohn's disease, and ulcerative colitis. We describe a case of an immediate hypersensitivity reaction to ustekinumab infusion with no reaction to subsequent ustekinumab subcutaneous maintenance therapy. We identify ethylenediaminetetraacetic acid as a unique excipient found in the intravenous formulation compared with the prefilled syringe used for subcutaneous injections, which is likely to account for this observation. No similar cases have been reported in the literature.
乌司奴单抗是一种抗白细胞介素（IL）-12和IL-23 p40亚基的单克隆抗体，已获美国食品药品监督管理局（FDA）批准用于治疗斑块状银屑病、中度至重度活动性克罗恩病和溃疡性结肠炎。我们报告了1例对乌司奴单抗静脉输注发生速发型超敏反应，但对随后的乌司奴单抗皮下维持治疗无反应的病例。我们确定乙二胺四乙酸是静脉制剂中与皮下注射用预填充注射器相比所特有的辅料，这可能是导致该现象的原因。文献中尚未报道过类似病例。
